Live News Categoriesmarket

KRYS.O (KRYS.O) News

Follow KRYS.O (KRYS.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol KRYS.O Asset market Sector Markets 90 days 1 Updated Oct 15, 2026, 11:07 AM UTC Open live news feed

L Krystal Biotech's KB113 Shrinks 83.1% of Assessed Basal Cell Carcinoma Lesions in Gorlin Syndrome Pilot Study Krystal Biotech reported regression in 83.1% of assessed basal cell carcinoma lesions with KB113 in a three-patient Gorlin syndrome pilot study. Non-injected lesions showed an 85.1% regression rate, providing preliminary CENTRAL_BANK | Oct 15, 2026, 11:07 AM UTC